Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data

Pharmaceutical Statistics

Volumn 13, Issue 4, 2014, Pages 238-246

  Kunz, Cornelia Ursula ^a   Friede, Tim ^b,c   Parsons, Nick ^a   Todd, Susan ^d   Stallard, Nigel ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d UNIVERSITY OF READING   (United Kingdom)

Author keywords

adaptive seamless design; multi arm multi stage trial; surrogate endpoint

Indexed keywords

ARTICLE; DATA ANALYSIS; DATA DRIVEN TREATMENT SELECTION; EXPERIMENTAL THERAPY; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; TREATMENT OUTCOME; TREATMENT PLANNING; COMPUTER SIMULATION; DECISION MAKING; PROCEDURES; STATISTICAL ANALYSIS;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84904425514     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1619     Document Type: Article

References (27)

1. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J,. Adaptive designs in clinical drug development-an executive summary of the pharma working group. Journal of Biopharmaceutical Statistics 2006; 16: 275-283.
2. Food and Drug Administration (FDA). Innovation or stagnation? challenge and opportunities on the critical path to new medical products, 2012. Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm (accessed November 28, 2012).
3. Phillips AJ, Keene ON,. Adaptive designs for pivotal trials: discussion points from the psi adaptive design expert group. Pharmaceutical Statistics 2006; 5 (1): 61-66.
4. Stallard N, Friede T,. A group-sequential design for clinical trials with treatment selection. Statistics in Medicine 2008; 27: 6209-6227.
5. Bretz F, Koenig F, Brannath W, Glimm E, Posch M,. Tutorial in biostatistics: adaptive designs for confirmatory clinical trials. Statistics in Medicine 2009; 28: 1181-1217.
6. Di Scala L, Glimm E,. Time-to-event analysis with treatment arm selection at interim. Statistics in Medicine 2011; 30: 3067-3081.
7. Brannath W, Koenig F, Bauer P,. Multiplicity and flexibility in clinical trials. Pharmaceutical Statistics 2007; 6 (3): 205-216.
8. Bretz F, Schmidli H, König F, Racine A, Maurer W,. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biometrical Journal 2006; 48: 623-634.
9. Stallard N,. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information. Statistics in Medicine 2010; 29: 959-971.
10. Friede T, Parsons N, Stallard N, Todd S, Valdés-Márquez E, Chataway J, Nicholas R,. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis. Statistics in Medicine 2011; 30: 1528-1540.
11. Liu Q, Pledger GW,. Phase 2 and 3 combination designs to accelerate drug development. Journal of the American Statistical Association 2005; 100: 493-502.
12. Todd S, Stallard N,. A new clinical trial design combining phases II and III: Sequential designs with treatment selection and a change of endpoint. Drug Information Journal 2005; 39: 109-118.
13. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Menard J,. Results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 2011; 124: 1945-1955.
14. Bretz F, Pinheiro JC, Branson M,. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics 2005; 61: 738-748.
15. Marcus R, Peritz E, Gabriel KR,. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63 (3): 655-660.
16. Bauer P, Köhne K,. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50 (4): 1029-1041.
17. Brannath W, Posch M, Bauer P,. Recursive combination tests. Journal of the American Statistical Association 2002; 97: 236-244.
18. Lehmacher W, Wassmer G,. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55 (4): 1286-1290.
19. Dunnett CW,. A multiple comparison procedure for comparing several treatments with a control. Journal of the American Statistical Association 1955; 50: 1096-1121.
20. Posch M, König F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P,. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 2005; 24: 3697-3714.
21. Kunz CU, Friede T, Parsons N, Todd S, Stallard N,. A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints. Journal of Biopharmaceutical Statistics. DOI: 10.1080/10543406.2013.840646.
22. Engel B, Walstra P,. Increasing precision or reducing expense in regression experiments by using information from a concomitant variable. Biometrics 1991; 47 (1): 13-20.
23. Galbraith S, Marschner IC,. Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes. Statistics in Medicine 2003; 22: 1787-1805.
24. Genz A, Bretz F, Miwa T, Mi X, Leisch F, Scheipl F, Bornkamp B, Hothorn T,. Package 'mvtnorm', 2012. Available at: http://CRAN.R-project.org (accessed 16.04.2014), R package version 0.9-9992.
25. R Development Core Team. R: A language and Environment for Statistical Computing, R Foundation for Statistical Computing: Vienna, Austria, 2011. Available at: http://www.R-project.org (accessed 16.04.2014), ISBN 3-900051-07-0.
26. Jenkins M, Stone A, Jennison C,. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 2011; 10 (4): 347-356.
27. Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M,. Adaptive seamless phase II/III designs-background, operational aspects, and examples. Drug Information Journal 2006; 40: 463-473.